(Q44114886)

English

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

scientific article published on 8 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

phase III clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Frederic Rolland

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jean-Luc Labourey

25

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Philippe Beuzeboc

17

object named as

Philippe Beuzeboc

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Guilhem Bousquet

32

object named as

Guilhem Bousquet

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Damien Pouessel

15

object named as

Damien Pouessel

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

7

object named as

Igor Latorzeff

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

8

object named as

Remy Delva

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

9

object named as

Ivan Krakowski

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Brigitte Laguerre

10

object named as

Brigitte Laguerre

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Gwenaelle Gravis

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Stéphane Oudard

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Franck Priou

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Benjamin Esterni

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christine Théodore

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Gael Deplanque

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jean Marc Ferrero

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Loïc Mourey

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sylvie Zanetta

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Muriel Habibian

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jean François Berdah

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jerome Dauba

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Marjorie Baciuchka

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christian Platini

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Claude Linassier

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jean Pascal Machiels

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Claude El Kouri

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Etienne Suc

29

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jean Christophe Eymard

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ali Hasbini

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Michel Soulie

33

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Karim Fizazi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

8 January 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

149-158

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

The economic burden of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome predictions for patients with metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive Partitioning

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The estimation of average hazard ratios by weighted Cox regression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant mitozantrone chemotherapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970560-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70560-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23306100%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44114886&oldid=2106727595"